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OBJECTIVES: In this study, we seek to measure the association between physician-
rated adherence to antihypertensive treatment and blood pressure outcomes. Prior
to the study, we hypothesized that systolic and diastolic blood pressure outcomes
were also related with patient and physician variables. Therefore, we also seek to
determine the impact of these variables on the outcome. METHODS: Unlike prior
adherence studies, which have consulted small sample sizes by means of time-
consuming and complex questionnaires, our research pools the findings from six
Valsartan studies, thereby evaluating 15,583 patients, while utilizing a simple and
cost-effective survey method. Adherence was measured using a four-item yes/no
Basel Assessment for Adherence Scale (BAAS), in which a “yes” answer on any item
classified a patient as non-adherent. The measurements were performed at base-
line and at 90 days. Hierarchical logistic regression was used to identify patient-
and physician-related determinants. RESULTS: Our results indicate that inade-
quate blood pressure control correlates with poor adherence at baseline and 90
days. The mean absolute difference in blood pressure between those who were
adherent (70% of the patient population) and those who were not was 5 to 19 mmHg
(p0.001). Every adherent patient was likely to decrease his systolic and diastolic
blood pressure by 2.3 and 1.3 mmHg, respectively (p0.001). The majority of the
variability in blood pressure values, however, was due to patient variables, many of
which can be managed with medical care, or identified in patients with higher
risks, poor adherence, or poly-pharmacy. CONCLUSIONS: Physician-reported ad-
herence by means of a short patient BAAS questionnaire is a direct, simple and
especially inexpensive method to assess adherence status. This method can be
easily integrated into routine clinical practice and provides evidence that adher-
ence is positively correlated with blood pressure reduction in hypertensive pa-
tients. However, patient-related variables also correlate strongly with the outcome
and demand further investigation.
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OBJECTIVES: To derive Australian utility values for different health states associ-
ated with a new antiarrhythmic drug, dronedarone, for the treatment of patients
with atrial fibrillation (AF). METHODS: ŒOne hundred nineteen participants were
recruited by an independent research company. They ranged from 18–69 years
(mean age 44 years). Participants were presented information about AF, as well as
treatment for their disease. Participants were then presented with 8 health states
describing AF and its treatment and were asked to value these using a standard
gamble technique. RESULTS: The results demonstrated that participants had a
strong understanding of the condition and its treatment, and successfully valued
the health states, applying values derived for the 8 health states (AF, mild stroke,
moderate stroke, severe stroke, myocardial infarction, mild stroke and myocardial
infarction, moderate stroke and myocardial infarction, and severe stroke and myo-
cardial infarction) and their varying severity levels in a logical sequence. Values
ranged from 0.41 (SD  0.25) for the health state describing a patient with severe
stroke and myocardial infarction, to 0.78 (SD  0.22) describing a patient experi-
encing a mild stroke. CONCLUSIONS: Overall, the results of this study show that a
sample of the general Australian population is able to use the standard gamble
successfully to derive utility values for atrial fibrillation health states.
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Thailand Stroke is the common cause of death and disability worldwide. Survived stroke patients
have impairment and pass to long term disability. A little is known what the health utility of Thai
stroke patients is.
OBJECTIVES: To measure health utility of stroke patients and to compare those
using 4 measurement methods, i.e., visual analogue scale (VAS), standard gamble
(SG), time trade off (TTO) and European Quality of Life–5 Dimensions (EQ-5D).
METHODS: All 284 stroke patients at Ratchaburi Hospital were recruited between
August to October 2009 with the following criteria; aged over 20 years, contained
the Barthel ADL Index scores of over 25 and be able to communicate. The patients
were invited to participate in the study and respond to the questionnaire. Six parts
of the questionnaire included general information, the Barthel ADL index, VAS, SG,
TTO and Thai EQ-5D. Difficulty of each assessment method was ranked. Data were
then analyzed by ANOVA. RESULTS: The mean health utility of stroke patients
measured by VAS, SG, and EQ-5D were 0.70, 0.72, and 0.55, respectively. However,
the score evaluated by TTO could not be measured since the questionnaires were
too difficult for patients to understand. In addition, there was no significant differ-
ence between health utility measured by VAS and SG. However, a significant dif-
ference between VAS and EQ-5D, and between SG and EQ-5D were found.
CONCLUSIONS: Thai stroke patients’ health utility was moderate level. However,
there was a significant difference in utilities obtained from different methods.
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BACKGROUND: Venous thrombembolism (VTE) is a frequent event in the devel-
oped world and is associated with serious long-term complications, including post-
thrombotic syndrome, recurrent VTE, poor health-related quality of life (HRQL) and
death. VTE can manifest as deep venous leg thrombosis or lung embolism.
OBJECTIVES: To examine factors associated with HRQL in a randomized, double-
blind phase III trial comparing dabigatran etexilate to dose-adjusted warfarin in
acute VTE (RE-COVER). METHODS: Following parenteral treatment of acute VTE,
patients were randomized to oral dabigatran etexilate or warfarin for six months.
Patients completed the EQ-5D questionnaire at baseline, three and six months.
EQ-5D index scores (UK weights) were regressed on treatment, time since index
VTE, age, gender, race, ethnicity, smoking status, body weight, and various clinical
characteristics/conditions. Multivariate Censored Least Absolute Deviations
(CLAD), Tobit and Ordinary Least Squares (OLS) regression methods were com-
pared. EQ-5D questionnaire responses were also examined to identify the most
affected domains. RESULTS: There were 1245 patients on warfarin and 1264 on
dabigatran with valid EQ-5D scores at baseline; 1149 and 1150, respectively, at trial
end. After controlling for covariates, the following factors were statistically signif-
icant (p0.05; CLAD) and exhibited the largest magnitude changes in EQ-5D index
scores (from largest to smallest): 6 months post VTE (0.21), 3 months post VTE
(0.192), recurrent DVT (-0.17), underweight (-0.09), female (-0.08), morbidly obese
(-0.07), recurrent pulmonary embolism (-0.06), heart failure (-0.05), age 65 (-0.04)
and clinically relevant bleeding (-0.03). There were no statistically significant dif-
ferences between treatment groups. All regression methods yielded comparable
results. Domains most affected by VTE were mobility, usual activities and
pain/discomfort. CONCLUSIONS: Results of the RE-COVER trial demonstrate that
HRQL after VTE is largely dependent on the time from event rather than choice of
treatment. Further, significant differences in HRQL were associated with certain
clinical and patient characteristics.
PCV111
ECONOMIC BURDEN AND HEALTH- RELATED QUALITY OF LIFE IN EUROPEAN
PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
Marrett E1, Dibonaventura MD2, Zhang Q3
1Merck, Sharp & Dohme, Whitehouse Station, NJ, USA, 2Kantar Health, New York, NY, USA,
3Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
OBJECTIVES: Assess the burden of peripheral arterial disease (PAD) on patient
health-related quality of life (HRQoL), work productivity, health care resource use,
and to estimate the related direct and indirect costs in patients with PAD in five EU
countries. METHODS: Cross-sectional data were obtained from the 2010 EU Na-
tional Health and Wellness Survey, an internet-based survey in adults. Patients
with PAD were identified based on a self-reported PAD diagnosis. We assessed
HRQoL (SF-12v2 and estimated health utility), healthcare resource use in previous
6 months and work productivity in previous 7 days (Work Productivity and Activity
Impairment questionnaire) reported by respondents with and without self-re-
ported PAD diagnosis. Resource use and work productivity loss were monetized on
an annual basis to provide per-person cost estimates (2010 Euros). RESULTS: We
identified 743 respondents with (France 278, Germany 151, UK 69, Italy 159, Spain
86) and 57,062 without PAD. Compared to non-PAD respondents, those self-report-
ing PAD were older (mean age 58.1 vs. 46.3 years), had more comorbidities, reported
lower mean (SD) HRQoL scores [mental summary: 43.4 (11.4) versus 46.6 (10.6);
physical summary: 37.6 (11.2) versus 48.8 (9.7); health utilities: 0.63 (0.12) versus
0.73 (0.13)], greater mean (SD) percentage of absenteeism [12.1 (27.7) versus 5.4
(19.2)], higher mean (SD) health care utilization over 6 months [physician office
visits 11.9 (13.7) versus 5.3 (7.4), emergency room visits 0.40 (1.6) versus 0.19 (1.1),
hospitalizations 0.39 (1.5) versus 0.13 (1.2)], and higher total median (SD) direct
[1,329 (3,198) versus 544 (2,630) €] and indirect [8,850 (10,244) versus 4,015 (7,135) €]
yearly costs. CONCLUSIONS: Respondents with self-reported PAD reported lower
HRQoL scores and generated greater direct and indirect costs suggesting that PAD
poses a significant health burden to patients and society in Europe. Better manage-
ment of PAD may improve patient quality of life and reduce societal costs associ-
ated with the disease.
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OBJECTIVES: To evaluate and compare patient satisfaction in stroke prevention in
atrial fibrillation (SPAF) in Europe. Interim results are presented to initiate discus-
sions and guide analysis for the main survey. METHODS: A survey based on the
Commonwealth Fund Survey (2008) for chronically ill adults is applied to patients
with SPAF, with few disease-specific adjustments made. The survey is carried out
with structured randomized anonymous telephone interviews in France, Ger-
many, Italy, Spain and UK, screening for respondents with AF aged over 18. Total
pilot sample size is 152 respondents, evenly divided per country. RESULTS: The
pilot results indicate differences to other chronically ill patients and country vari-
ations. Mean age of respondents is 67, 50% female. Overall, 43% of the respondents
are totally satisfied with their health care system (highest in the UK: 57%). Most
frequent co-morbidities are hypertension (66%) and heart disease, including heart
attack (53%) beside arthritis, depression, chronic lung problems, diabetes, cancer –
with an average of 2,2 co-morbidities per respondent, regularly on 5,4 different
prescriptions. Ten percent had a period when they were uninsured (highest with
20% in the UK) and 11% had problems with unpaid medication (highest in Germany
with 33%) or refusal of payment by the insurance 9% (highest in France with 27%).
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